Competitive Technologies to Showcase Pain Management Medical Device At Conference in India

FAIRFIELD, Conn., Feb. 4, 2009 (GLOBE NEWSWIRE) -- Competitive Technologies,
Inc. (NYSE Alternext US:CTT) announced today that CTT's pain management medical
device will be showcased by Excel Life Sciences, Inc. (ELS), CTT's
country-exclusive device distributor in India, at the International Conference
of Indian Association of Palliative Care (IAPCON) in New Delhi. The conference
has been organized around the theme, "Freedom From Pain." ELS's booth can be
visited on February 13-15 at the IAPCON Exhibition Hall at Booth 4. The medical
device is a non-invasive method for rapid treatment of high-intensity oncologic
and neuropathic pain, including pain resistant to morphine and other drugs. 

ELS is conducting clinical trials for the device at four separate medical
institutions in India, with a planned enrollment of 160 patients. The studies
are expected to further support five earlier clinical trials conducted in Italy
that conformed to the Helsinki Declaration, which is a standard that is also
accepted by the US FDA. The Italian clinical trials covered over 1,000 subjects
suffering from chronic oncologic or neuropathic pain not responding to standard
therapeutic protocols, including morphine. Results from the Italian clinical
trials validated the efficacy of the device and indicated that it was extremely
efficient from both a clinical and statistical respect. The treatment method
was found to be an important resource for pain therapists treating cases not
responding to other types of treatment. 

ELS, a U.S.-based, India-focused provider of clinical research and healthcare
services, has a special focus on improving patient care in the markets in which
they operate. ELS has a fully-owned Indian subsidiary with its main office in
New Delhi, and 21 operational locations serving a network of over 700 hospitals
across India. 

The CTT device has Medical Device CE certification from the European Union
allowing sales of the device throughout Europe and several other countries,
including India. Approval of CTT's pending FDA 510(k) medical device
application will authorize U.S. sales of the device. The review and selection
process for distributors in Europe, Asia, the U.S. and Latin America is
continuing. CTT has exclusive worldwide rights to this patented device.
Additional distribution agreements granted country-exclusive distribution
rights to GEOMC Co., Ltd. for Korea, to AG Healthcare for Malaysia, and to
Biogene Pharma Limited for Bangladesh. 

"We believe that ELS's studies will provide further support of the strength and
excellence of CTT's pain management device," said Aris D. Despo, CTT's
Executive VP, Business Development. "Together with the earlier Italian trials,
conducted by leading medical authorities in Italy, including Tor-Vergata, the
trials have all been conducted under the globally recognized Helsinki
Declaration." 

"We believe that the financial results generated by this medical device will
have the potential to significantly increase CTT's market capitalization," said
John B. Nano, CTT's Chairman, President and CEO. "This medical device is a
prime example of our business strategy to connect clinical science to patient
care, improving healthcare for mankind." 

Developed in Italy by CTT's client, Prof. Giuseppe Marineo, the technology was
brought to CTT through the efforts of Prof. Giancarlo Elia Valori of the
Italian business development group, Sviluppo Lazio S.p.A., and assistance from
the Zangani Investor Community(tm). The technology, with a biophysical rather
than a biochemical approach, uses a multi-processor able to simultaneously
treat multiple pain areas by applying surface electrodes to the skin. CTT
partner, GEOMC Co., Ltd. of Korea, is manufacturing the device commercially for
worldwide distribution. For more information on the device, visit
www.CalmareTT.com. 

The device has been used on over 3,000 patients in Europe, including at the
Pain Management Center at Tor-Vergata University Medical Center in Rome
(www.ptvonline.it/uo_ter_ant_ing.asp), and at Fondazione Parco Biomedico San
Raffaele in Rome (www.scienceparkrome.eu). 

About Excel Life Sciences, Inc. 

ELS is a U.S.-based, India-focused provider of comprehensive clinical research
and healthcare services, helping to advance science and improve patient care.
ELS is a privately owned Delaware corporation, with 21 operational locations
across India and a network of approximately 1,000 physicians serving over 700
hospitals. ELS has U.S. offices in Boston, Chicago, and Durham, N.C. Its
success is built around passionate and experienced individuals working
alongside clients to accelerate clinical research and deliver new drugs and
medical devices to the markets, while maintaining the highest standards of
quality. ELS is committed to improving and expanding the clinical research
enterprise in India. Visit ELS's website: www.ExcelLifeSciences.com 

About Competitive Technologies, Inc. 

Competitive Technologies, established in 1968, provides distribution, patent
and technology transfer, sales and licensing services focused on the needs of
its customers and matching those requirements with commercially viable product
or technology solutions. CTT is a global leader in identifying, developing and
commercializing innovative products and technologies in life, electronic, nano,
and physical sciences developed by universities, companies and inventors. CTT
maximizes the value of intellectual assets for the benefit of its customers,
clients and shareholders. Visit CTT's website: www.competitivetech.net 

Statements made about our future expectations are forward-looking statements
and subject to risks and uncertainties as described in our most recent Annual
Report on Form 10-K for the year ended July 31, 2008, filed with the SEC on
October 28, 2008, and other filings with the SEC, and are subject to change at
any time. Our actual results could differ materially from these forward-looking
statements. We undertake no obligation to update publicly any forward-looking
statement. 

CONTACT:  IR Services, LLC
          Johnnie D. Johnson
          860 434 2465
          jdjohnson@corpirservices.com